In vitro lung deposition of fluticasone propionate/formoterol (FP/FORM) pressurized metered dose inhaler (pMDI) with different inhalation profiles Source: International Congress 2014 – Asthma and COPD devices and treatments Year: 2014
The effect of inhalation duration on lung deposition with a pressurized metered-dose inhaler (pMDI) Source: International Congress 2014 – Asthma and COPD devices and treatments Year: 2014
High dose extrafine beclomethasone/formoterol via metered dose inhaler is effective and safe in asthmatics not controlled on medium-high dose of inhaled corticosteroids Source: International Congress 2014 – Asthma and COPD management Year: 2014
Lung deposition analysis of two formulations of fluticasone/salmeterol HFA pMDI in stable asthma patients Source: International Congress 2014 – Novel approaches and evidence for drug development in respiratory diseases Year: 2014
Comparison of the particle size distribution of fluticasone propionate/formoterol and beclometasone/formoterol MDI using laser diffraction Source: International Congress 2014 – Rationale behind respiratory drug development Year: 2014
Effect of interval between actuations of albuterol HFA inhalers on their aerosol characteristics Source: International Congress 2016 – Paediatric asthma: recurrent, persistent, or severe obstruction and lung function techniques Year: 2016
Plume temperature and force of fluticasone propionate/formoterol pMDI compared with fluticasone propionate/salmeterol pMDI Source: International Congress 2014 – Novel evidence relating to respiratory treatment development Year: 2014
Dose-proportional lung bioavailability of beclometasone dipropionate and formoterol fumarate across three different dose strenghts of CHF1535 pMDI Source: Annual Congress 2013 –Asthma and COPD drugs: efficacy, safety and pharmacoeconomics Year: 2013
Tiotropium respimat: Comparison of bronchodilator efficacy of 5 and 2.5 µg doses Source: International Congress 2014 – Asthma and COPD devices and treatments Year: 2014
Effects of extra fine formoterol or coarse particle salmeterol on impulse oscillometry (IOS) in corticosteroid treated persistent asthmatics Source: International Congress 2015 – Safety of and interactions between current treatments for asthma and COPD Year: 2015
Are extra-fine particles from dry powder inhalers likely to improve lung deposition? Source: International Congress 2014 – Asthma and COPD devices and treatments Year: 2014
Mixed treatment analysis comparing tiotropium HandiHaler® and Respimat® Source: International Congress 2014 – Asthma and COPD devices and treatments Year: 2014
In vitro validation of the use of a spacer with an extrafine beclomethasone/formoterol formulation Source: International Congress 2016 – Pulmonary drug delivery Year: 2016
Are ultrafine particle inhalers, better for patients with small airway involvement? Source: International Congress 2014 – Novel evidence relating to respiratory treatment development Year: 2014
Mometasone furoate delivered via the Breezhaler® and Twisthaler® devices in asthma Source: International Congress 2014 – Asthma and COPD devices and treatments Year: 2014
Effect of the actuator orifice diameter on the biodisposition of a new budesonide CFC-free metered dose inhaler formulation Source: Eur Respir J 2001; 18: Suppl. 33, 102s Year: 2001
Inhaled long-acting β2 -agonist: aerosol particle size and bronchodilator response Source: Eur Respir J 2005; 26: Suppl. 49, 126s Year: 2005
Study design supporting the effectiveness of inhaled extra-fine beclomethasone/formoterol at the level of small airways of asthmatics Source: Annual Congress 2013 –Asthma drugs: new findings Year: 2013
Broncho dilator response to salbutamol delivered by metered dose inhaler with spacer versus dry powder inhaler in acute asthma in children Source: International Congress 2016 – Drugs, bugs, BMI, and other problems in paediatric asthma Year: 2016
In vitro comparison of output and particle size distribution of budesonide from metered-dose inhaler with three spacer devices during pediatric tidal breathingSource: Eur Respir J 2005; 26: Suppl. 49, 161s Year: 2005